Premium
Inhibition of hepatic drug metabolism by noret
Author(s) -
Field Barry,
Lu Cherry,
Hepner Gershon W.
Publication year - 1979
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1979252196
Subject(s) - progestogen , drug metabolism , medicine , endocrinology , metabolism , glucuronidation , metabolic clearance rate , drug , hepatic function , demethylation , menstrual cycle , chemistry , pharmacology , microsome , pharmacokinetics , estrogen , hormone , in vitro , biochemistry , gene expression , dna methylation , gene
In order to assess the effect of norethindrone on hepatic drug metabolism in man, hepatic N‐demethylation of aminopyrine was studied by means of the aminopyrine breath test (ABT) in 7 healthy women during two menstrual cycles. Aminopyrine metabolic clearance rates were also studied in 3 women. The women were examined at the ends of the first, second, and third weeks before starting progestogen therapy and at the same times during a second menstrual cycle during which they took norethindrone, 350 µ/day. The ABT was 5.1 ± 1.9% (mean ± SD) during the three control weeks and lower (p < 0.001) during the three weeks on norethindrone, 3.9 ± 0.9%. Aminopyrine metabolic clearance rate also fell during norethindrone therapy. The data suggest that progestogens inhibit hepatic microsomal function.